Last reviewed · How we verify
NCT01536327: BioMeta
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease
trial in Peripheral Neuropathy. Withdrawn.
28 February 2021
Quick facts
| Lead sponsor | CENTOGENE GmbH Rostock |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 20 August 2018 |
| Primary completion | 28 February 2021 |
| Estimated completion | 28 February 2021 |
| Sites | 5 locations across Sri Lanka, Germany, Egypt, India |
Conditions studied
- Peripheral Neuropathy — all drugs for Peripheral Neuropathy →
- Muscle Weakness — all drugs for Muscle Weakness →
Sponsor
CENTOGENE GmbH Rostock
Who can join
1 Day and older, any sex, with Peripheral Neuropathy or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Development of a new MS-based biomarker for the early and sensitive diagnosis of Metachromatic Leu-kodystrophy disease from blood (plasma)
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Disease specific therapies in leukodystrophies and leukoencephalopathies.
Helman G, Van Haren K, Bonkowsky JL, Bernard G, et al · · 2015 · cited 40× · PMID 25684057 · DOI 10.1016/j.ymgme.2015.01.014 -
Emerging treatments for pediatric leukodystrophies.
Helman G, Van Haren K, Escolar ML, Vanderver A. · · 2015 · cited 14× · PMID 26022168 · DOI 10.1016/j.pcl.2015.03.006
Verify or expand the search:
- PubMed search for NCT01536327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Neuropathy
Currently open trials in the same condition.
- NCT07336381 — Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy · NA · recruiting
- NCT07025005 — Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VR · Phase 4 · recruiting
- NCT07163000 — Earlier Diagnosis of Peripheral Neuropathy Using A Simple sCreening Tool (ACT) · active not recruiting
- NCT07055711 — Association Between Work-Related Stress and Peripheral Neuropathic Pain in Female Breast Cancer Post CT · active not recruiting
- NCT06615622 — Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic · recruiting
Other CENTOGENE GmbH Rostock trials
Trials by the same sponsor.
- NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
- NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
- NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
- NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
- NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01536327 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
- Last refreshed: 13 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01536327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing